C-reactive protein: A differential biomarker for major depressive disorder and bipolar II disorder

References

• Almeida JR, Mourao-Miranda J, Aizenstein HJ, Versace A, Kozel FA, Lu H, et al. 2013. Pattern recognition analysis of anterior cingulate cortex blood flow to classify depression polarity. Br J Psychiatry. 203:310–311.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. 2010. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 167:792–800.
   PubMed Web of Science ®Google Scholar
• Anand A, Li Y, Wang Y, Lowe MJ, Dzemidzic M. 2009. Resting state corticolimbic connectivity abnormalities in unmedicated bipolar disorder and unipolar depression. Psychiatry Res. 171:189–198.
   PubMed Web of Science ®Google Scholar
• Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E, Gamma A, et al. 2011. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry. 68:791–798.
   PubMed Web of Science ®Google Scholar
• Bai YM, Su TP, Tsai SJ, Wen-Fei C, Li CT, Pei-Chi T, et al. 2014. Comparison of inflammatory cytokine levels among type I/type II and manic/hypomanic/euthymic/depressive states of bipolar disorder. J Affect Disord. 166:187–192.
   PubMed Web of Science ®Google Scholar
• Becking K, Boschloo L, Vogelzangs N, Haarman BC, Riemersma-van der Lek R, Penninx BW, et al. 2013. The association between immune activation and manic symptoms in patients with a depressive disorder. Transl Psychiatry. 3:e314.
   PubMed Web of Science ®Google Scholar
• Benazzi F. 2007. Bipolar disorder–focus on bipolar II disorder and mixed depression. Lancet. 369:935–945.
   PubMed Web of Science ®Google Scholar
• Beurel E, Jope RS. 2014. Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits. Transl Psychiatry. 4:e488.
   PubMed Web of Science ®Google Scholar
• Blacker D, Tsuang MT. 1992. Contested boundaries of bipolar disorder and the limits of categorical diagnosis in psychiatry. Am J Psychiatry. 149:1473–1483.
   PubMed Web of Science ®Google Scholar
• Bowden CL. 2010. Diagnosis, treatment, and recovery maintenance in bipolar depression. J Clin Psychiatry. 71:e01.
   Google Scholar
• Chang HH, Lee IH, Gean PW, Lee S-Y, Chi MH, Yang YK, et al. 2012. Treatment response and cognitive impairment in major depression: association with C-reactive protein. Brain Behav Immun. 26:90–95.
   PubMed Web of Science ®Google Scholar
• Chou CC, Lee IH, Yeh TL, Chen KC, Chen PS, Chen WT, et al. 2012. Comparison of the validity of the Chinese versions of the Hypomania Symptom Checklist-32 (HCL-32) and Mood Disorder Questionnaire (MDQ) for the detection of bipolar disorder in medicated patients with major depressive disorder. Int J Psychiatry Clin Pract. 16:132–137.
   PubMed Web of Science ®Google Scholar
• Culpepper L. 2014. Misdiagnosis of bipolar depression in primary care practices. J Clin Psychiatry. 75:e05.
   Google Scholar
• Daigneault A, Duclos C, Saury S, Paquet J, Dumont D, Beaulieu S. 2015. Diagnosis of bipolar disorder in primary and secondary care: What have we learned over a 10-year period? J Affect Disord. 174:225–232.
   PubMed Web of Science ®Google Scholar
• Dargél AA, Godin O, Kapczinski F, Kupfer DJ, Leboyer M. 2015. C-Reactive Protein Alterations in Bipolar Disorder: a Meta-Analysis. J Clin Psychiatry. 76:142–150.
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. 2007. Elevated serum levels of C-reactive protein are associated with mania symptoms in outpatients with bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 31:952–955.
   PubMed Web of Science ®Google Scholar
• Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. 2013. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 150:456–459.
   PubMed Web of Science ®Google Scholar
• Dudek D, Siwek M, Zielinska D, Jaeschke R, Rybakowski J. 2013. Diagnostic conversions from major depressive disorder into bipolar disorder in an outpatient setting: results of a retrospective chart review. J Affect Disord. 144:112–115.
   PubMed Web of Science ®Google Scholar
• Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. 2011. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 168:40–48.
   PubMed Web of Science ®Google Scholar
• Fond G, Hamdani N, Kapczinski F, Boukouaci W, Drancourt N, Dargel A, et al. 2014. Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand. 129:163–179.
   PubMed Web of Science ®Google Scholar
• Frankland A, Cerrillo E, Hadzi-Pavlovic D, Roberts G, Wright A, Loo CK, et al. 2015. Comparing the phenomenology of depressive episodes in bipolar I and II disorder and major depressive disorder within bipolar disorder pedigrees. J Clin Psychiatry. 76:32–39.
   PubMed Web of Science ®Google Scholar
• Halder I, Marsland AL, Cheong J, Muldoon MF, Ferrell RE, Manuck SB. 2010. Polymorphisms in the CRP gene moderate an association between depressive symptoms and circulating levels of C-reactive protein. Brain Behav Immun. 24:160–167.
   PubMed Web of Science ®Google Scholar
• Hamer M, Batty GD, Marmot MG, Singh-Manoux A, Kivimaki M. 2011. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav Immun. 25:168–173.
   PubMed Web of Science ®Google Scholar
• Hantouche EG, Akiskal HS, Lancrenon S, Allilaire JF, Sechter D, Azorin JM, et al. 1998. Systematic clinical methodology for validating bipolar-II disorder: data in mid-stream from a French national multi-site study (EPIDEP). J Affect Disord. 50:163–173.
   PubMed Web of Science ®Google Scholar
• Harrison NA, Cercignani M, Voon V, Critchley HD. 2015. Effects of inflammation on hippocampus and substantia nigra responses to novelty in healthy human participants. Neuropsychopharmacology. 40:831–838.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM. 2014. Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord. 169:S12–S16.
   PubMed Web of Science ®Google Scholar
• Hodes GE, Pfau ML, Leboeuf M, Golden SA, Christoffel DJ, Bregman D, et al. 2014. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA. 111:16136–16141.
   PubMed Web of Science ®Google Scholar
• Huang TL, Lin FC. 2007. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry. 31:370–372.
   PubMed Web of Science ®Google Scholar
• Hung Chi M, Hua Chang H, Tzeng NS, Huang SY, Chou KR, Chun Tsai H, et al. 2013. The prevalence of metabolic syndrome in drug-naive bipolar II disorder patients before and after twelve week pharmacological intervention. J Affect Disord. 146:79–83.
   PubMed Web of Science ®Google Scholar
• Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, et al. 2012. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 141:1–10.
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Chen S-L, Chang Y-H, Chen PS, Huang S-Y, Tzeng N-S, et al. 2013. Inflammation’s Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder. PLoS ONE. 8:e66847.
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE. Jr., et al. 2006. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 163:232–239.
   PubMed Web of Science ®Google Scholar
• Li CT, Bai YM, Huang YL, Chen YS, Chen TJ, Cheng JY, et al. 2012. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry. 200:45–51.
   PubMed Web of Science ®Google Scholar
• Lovdahl H, Boen E, Malt EA, Malt UF. 2014. Somatic and cognitive symptoms as indicators of potential endophenotypes in bipolar spectrum disorders: An exploratory and proof-of-concept study comparing bipolar II disorder with recurrent brief depression and healthy controls. J Affect Disord. 166:59–70.
   PubMed Web of Science ®Google Scholar
• Mansur RB, Brietzke E, McIntyre RS. 2015. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 52:89–104.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Zacho J. 2009. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? Nutr Metab Cardiovasc Dis. 19:521–524.
   PubMed Web of Science ®Google Scholar
• O'Brien SM, Scott LV, Dinan TG. 2006. Antidepressant therapy and C-reactive protein levels. Br J Psychiatry. 188:449–452.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, et al. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:499–511.
   PubMed Web of Science ®Google Scholar
• Pepe M, Longton G, Janes H. 2009. Estimation and comparison of receiver operating characteristic curves. Stata J. 9:1–1.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, McIntyre RS. 2015. Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand. 132:180-191.
   PubMed Web of Science ®Google Scholar
• Sing T, Sander O, Beerenwinkel N, Lengauer T. 2005. ROCR: visualizing classifier performance in R. Bioinformatics. 21:3940–3941.
   PubMed Web of Science ®Google Scholar
• Tsai SY, Chung KH, Huang SH, Chen PH, Lee HC, Kuo CJ. 2014. Persistent inflammation and its relationship to leptin and insulin in phases of bipolar disorder from acute depression to full remission. Bipolar Disord. 16:800–808.
   PubMed Web of Science ®Google Scholar
• Vogelzangs N, Beekman AT, van Reedt Dortland AK, Schoevers RA, Giltay EJ, de Jonge P, et al. 2014. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology. 39:1624–1634.
   PubMed Web of Science ®Google Scholar
• Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W, et al. 2012. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry. 2:e79.
   PubMedGoogle Scholar
• Watkins CC, Sawa A, Pomper MG. 2014. Glia and immune cell signaling in bipolar disorder: insights from neuropharmacology and molecular imaging to clinical application. Transl Psychiatry. 4:e350.
   Google Scholar
• Wei W, Yang S, Qiu Y, Wang H, Zhao X, Zhao Y, et al. 2014. CRP gene polymorphism contributes genetic susceptibility to dyslipidemia in Han Chinese population. Mol Biol Rep. 41:2335–2343.
   PubMed Web of Science ®Google Scholar
• Wysokinski A, Margulska A, Strzelecki D, Kloszewska I. 2015. Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder. Nord J Psychiatry. 69:346–353.
   PubMed Web of Science ®Google Scholar
• Ximenes JC, de Oliveira Goncalves D, Siqueira RM, Neves KR, Santos Cerqueira G, Correia AO, et al. 2013. Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties. Naunyn Schmiedebergs Arch Pharmacol. 386:575–587.
   PubMed Web of Science ®Google Scholar